US 11174212
2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
granted A61KA61K31/05A61K31/122
Quick answer
US patent 11174212 (2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders) held by PTC THERAPEUTICS, INC. expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61K, A61K31/05, A61K31/122, A61P, A61P25/16